Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N07BC01

Buvidal(buprenorphine)

Opioid-Related Disorders

Marketing Authorisation Holder: Camurus AB

EMA Authorisation: 20/11/2018

INN: buprenorphine

Indication

Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Buvidal — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.